Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Human Reproductive Technologies Market $37.1 Billion by 2027

The global market for human reproductive technologies estimated to reach $37.1 billion by 2027, expanding at a CAGR of 5.4% over the forecast period, driven by growing concerns of infertility and childlessness among people and increasing cases of genetic diseases around the world.

  • In view of the global burden of subfertility, efforts are required to make assisted reproduction more effective, less burdensome and more equally accessible. Therefore, new reproductive technologies are frequently introduced in clinical practice that are efficacious, effective and/or safe.
    • Other factors driving the market growth include increasing prevalence of unwanted pregnancies, unmet contraceptive needs, and government support for contraceptive products.
Global Human Reproductive Technologies Market

A number of technological advances have revolutionized human reproduction in the past few decades. One example is in vitro fertilizations (IVF). Other examples include embryo transfer and pre-implantation genetic testing. 

  • Human reproductive technology (HRT) encompasses all current and anticipated uses of technology, including assisted reproductive technology, contraception and others.
    • For example, the assisted reproductive technology (ART) is used to achieve pregnancy in procedures such as fertility medication, artificial insemination, in vitro fertilization and surrogacy, and it is primarily used for infertility treatments.
      • It mainly belongs to the field of reproductive endocrinology and infertility, and may also include intracytoplasmic sperm injection (ICSI) and cryopreservation.
  • However, some countries do not permit pre-implantation genetic testing at all. Many others, among them Australia, Belgium, Canada, France, Germany, Italy, India, the Netherlands, Spain, Switzerland and the UK, do not permit it for the purpose of choosing the baby’s sex.
Global Contraceptive Use - Modern Methods
Global Contraceptive Use - Traditional Methods

According to European Society of Human reproduction and Embryology (ESHRE),
approximately 9% of women aged 20-44 years worldwide are estimated to be infertile.

  • It has been observed that 30% to 35% of infertility cases are explained due to physiological causes in women.
    • Approximately 20-25% of cases, both male and female are responsible for the infertility. Men are responsible for 30-35% of the infertility cases and in approximately 5-10% of cases real cause behind infertility is unknown.
      • Some of the major causative factors for female infertility include endometriosis, ovulatory dysfunction, tubal factors and diminished ovarian reserve. While some of the male infertility factors include azoospermia, sperm dysfunction and varicoceles.

Source: United Nations Population Division

Human Reproductive Technologies Market

The global human reproductive technologies market report provides market size ($million 2017 to 2027), market volume (number of procedures), market share, growth trends and forecast (CAGR%, 2021 to 2027). 

The global market for human reproductive technologies segmented by infertility drugs [Gonal-f (recombinant follitropin alfa), Follistim AQ (follitropin beta), AndroGel (testosterone), Testim (testosterone), Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil)], infertility procedure type [in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), zygote intrafallopian transfer (ZIFT), gamete intrafallopian transfer (GIFT), intrauterine insemination (IUI)], contraceptive drugs (oral contraceptive pills, contraceptive injectables, topical contraceptives), contraceptive devices [male contraceptive devices (male condoms), female contraceptive devices], and geography.

  • Infertility drugs majorly include hormones responsible for ovulation and spermatogenesis in females and males respectively. The global infertility drugs market is characterized by the presence of large number of marketed female infertility treatment products. Therefore, the market for male infertility treatment is underserved with very few marketed products.
    • Among the seven branded formulations of infertility drugs, the Viagra (sildenafil citrate) segment accounted for the largest share of the total market, followed by the Cialis (tadalafil) segment, belonging to the class of selective phosphodiesterase type 5 (PDE-5) inhibitors.
      • Pfizer, Inc’s Viagra is one of the most widely sold and distributed erectile dysfunction products worldwide. Viagra’s primary competitors in the market include Eli Lilly & Co’s Cialis (tadalafil) and Bayer AG’s Levitra (vardenafil).
  • According to CDC, ART procedures usage has been doubled over last one decade and more than 1% of all the babies born in the U.S. are conceived utilizing the ART procedures every year.
    • Based on CDC’s 2017 Fertility Clinic Success Rates Report, there were 284,385 ART cycles performed at 448 reporting clinics in the U.S., resulting in 68,908 live births and 78,052 live born infants. 
      • Similarly, according to the Human Fertilization and Embryology Authority (HFEA), U.K., around 60,000 infertility treatments are performed each year in United Kingdom’s licensed clinics.
        • In the recent years, the intra-uterine insemination (IUI) and intra-cytoplasmic sperm injection (ICSI) procedures to treat infertility are gaining much popularity as well as acceptance across geographies.
  • Based on the contraceptive treatments, the contraceptive devices segment dominated the global market and also expected to witness the fastest growth rate in the coming years.
    • Out of this, the female contraceptive devices such as the female condoms, contraceptive diaphragms, intrauterine devices (IUD), subdermal contraceptive implants, contraceptive sponges and vaginal rings segment accounted for the slightly larger revenue share of global market.
      • However, the make contraceptive devices segment anticipated to register highest CAGR during the forecast period, since male condom is one of the most prevalent, highly effective and relatively cheaper contraceptive devices in the world, compared to other contraceptive products.

The global market for human reproductive technologies research report is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA) and Rest of the World.

The global market for human reproductive technologies report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major competitors operating in global market for human reproductive technologies and included in the report are Abbott Laboratories, Inc., Actavis, Inc., Bayer AG, Church & Dwight, Co. Inc., Cook Medical, Inc., Ferring International Center S.A., Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Reckitt Benckiser Group plc, Teva Pharmaceutical Industries Ltd., and Warner Chilcott plc.

  • Infertility Treatment
    • Infertility Drugs
      • Gonal-f (Recombinant Follitropin Alfa)
      • Follistim AQ (Follitropin Beta)
      • AndroGel (Testosterone)
      • Testim (Testosterone)
      • Viagra (Sildenafil Citrate)
      • Cialis (Tadalafil)
      • Levitra/Staxyn (Vardenafil)
    • Infertility Procedure / Assisted Reproductive Technology (ART)
      • In Vitro Fertilization (IVF)
      • Intracytoplasmic Sperm Injection (ICSI)
      • Zygote Intrafallopian Transfer (ZIFT)
      • Gamete Intrafallopian Transfer (GIFT)
      • Intrauterine Insemination (IUI)
  • Contraceptive Treatment
    • Contraceptive Drugs
      • Oral Contraceptive Pills
      • Contraceptive Injectables
      • Topical Contraceptives
    • Contraceptive Devices
      • Male Contraceptive Devices (Male Condoms)
      • Female Contraceptive Devices
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Abbott Laboratories, Inc.
    • Actavis, Inc.
    • Bayer AG
    • Church & Dwight, Co. Inc.
    • Cook Medical, Inc.
    • Ferring International Center S.A.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Pfizer, Inc.
    • Reckitt Benckiser Group plc
    • Teva Pharmaceutical Industries Ltd.
    • Warner Chilcott plc

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 463-5840
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]